Albert Einstein College of Medicine-Yeshiva University
Fellowship, Rheumatology
Hospital for Special Surgery
Certifications
American Board of Internal Medicine
Awards
2009
EULAR Basic Sciences Abstract Award
2005
The Charles Christian Research Fellowship
2003
ACR Rheumatology Fellow Award
2002
Rheumatology Fellowship Award
Amgen
2002
Abbott Scholar Award in Rheumatology Research
1996
American Society of Nephrology Blue Ribbon Award
1996
American College of Rheumatology (ACR) Research and Education Foundation Award
Research
Cytokines and the Jak-STAT signaling pathway.
Cytokines are secreted proteins that mediate communication between cells and are critical for the development and regulation of the immune response. Cytokines act by binding with high affinity and specificity to cell surface receptors, triggering signal transduction pathways that ultimately lead to gene activation cascades that regulate cellular activation, differentiation, proliferation and survival. Deregulation of cytokine production or cytokine networks have been implicated in the pathogenesis of a number of human autoimmune/ inflammatory diseases including SLE. Cytokines relay their intracellular signals by utilizing the Jak-Stat signal transduction pathway. The binding of the cytokines to their receptors that lack intrinsic kinase activity, activates Janus kinases (Jaks), protein tyrosine kinases that are associated with the receptor. Typically each cytokine activates a distinct pair of of two of the four known Jaks. Jak kinases are required for tyrosine phosphorylation and activation of latent cytoplasmic transcription factors termed signal transducers and activators of transcription (STATs). After cytokine stimulation, STATs are rapidly tyrosine phosphorylated, and subsequently dimerize and translocate to the nucleus, where they can activate gene transcription. Tyrosine phosphorylation of STATs is essential for activation, dimerization and DNA binding. We have shown that IFN signaling is regulated by crosstalk with the ITAM-Syk pathway, a signal transduction pathway that is used specifically by immune cells and is key in cell activation. Crosstalk between IFN and Syk-mediated pathways is not static but depends on the activation state of macrophages and is induced by priming with IFN (Fig. 2). Thus, macrophage responses to IFN are determined by integration of signals from two main pathways that regulate immune responses (1). Thus, the nature of cytokine responses can be altered or reprogrammed by the nature of a particular stimulus or the microenvironment that the cells are exposed.
Immune cell receptors
A growing number of receptors including the Toll-like receptors (TLRs) and receptors that transmit signals via the ITAM containing adaptor molecules FcR and DAP12 play important roles in the activation status of the cells of the immune system. Activation of these receptors by their ligands seems to be very important for effective development and resolution of an immune response. Signaling pathways activated downstream of these receptors include the NF-kB, MAPKs, PI3K and Ca++-induced pathways that play a central role in the activation, differentiation and survival of the cells. There is experimental evidence of regulation and crosstalk between cytokine and immune receptor signaling in cells of the immune system. A paradigm is the inhibition of interleukin-10 (IL-10) signaling in macrophages after ligation of the FcgRs by immune complexes (2). In this case macrophages become refractory to the anti-inflammatory actions of IL-10, a mechanism that may play important role in the perpetuation of inflammation in diseases characterized by the presence of immune complexes such as inflammatory arthritis and systemic lupus erythematosus.
Tpl2 kinase
Tumor progression locus 2 (Tpl2) encodes a serine/threonine protein kinase that is activated by provirus integration in Moloney murine leukemia virus-induced T cell lymphomas and mouse mammary tumor virus-induced mammary adenocarcinomas. Tpl2 transduces Toll-like and death receptor signals in a variety of cell types and plays an important role in innate immunity and inflammation. Tpl2 knockout (Tpl2-/-) mice develop normally and have no obvious phenotypic defects. However, Tpl2-/- mice are resistant to LPS-induced endotoxin-shock, as well as to TNF-induced inflammatory bowel disease. Tpl2 plays an obligatory role in the transduction of extracellular signal-regulated kinase (ERK) activation signals induced by LPS and CD40L inmacrophages and B cells and by TNF in macrophages. The failure of ERK activation by LPS in Tpl2-/- macrophages gives rise to defects in the expression of cytokines, chemokines and other molecules involved in the regulation of innate and adaptive immunity. We have shown that Tpl2 kinase is activated downstream of the FcgRs and regulate phagocytosis and cytokine and chemokine production. Moreover in an animal model of immune thrombocytopenia pharmacological targeting of Tpl2 prevented the development of thrombocytopenia. These data identify Tpl2 kinase as a potential therapeutic target for autoimmune diseases.
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Patients with Healthfirst Medicare Advantage insurance: Effective , Mount Sinai’s primary care providers (internal medicine, family practice, and geriatrics) are not accepting new Healthfirst Medicare patients. Please contact Healthfirst for help finding a primary care provider. Healthfirst Medicare members who have a relationship with a Mount Sinai primary care provider can continue to book appointments with them.
17 East 102nd Street, 2nd Floor, New York, NY, 10029
1199 SEIU
AETNA - Commercial
AETNA - Medicare
Affinity Medicaid-Medicare-Essential Exchange
CIGNA Healthcare
Centivo
Cigna - Medicare
Elderplan
EmblemHealth - GHI-PPO
EmblemHealth - HIP
EmblemHealth - HIP-Medicaid
EmblemHealth - HIP-Medicare
Empire Blue Cross Blue Shield - Commercial/Exchange
Empire Blue Cross Blue Shield - HealthPlus Medicaid
Empire Blue Cross Blue Shield - Medicare
Fidelis Health Care
HealthFirst Medicaid
HealthFirst Medicare
Horizon NJ
Hotel Trades
Humana Medicare
Magnacare-Health Care
Medicare - NJ
Medicare - NY
Multiplan PHCS
NJ Medicaid
NY Medicaid
Oscar
Oxford - Freedom and Liberty
Partners Health Plan
Senior Whole Health
United Health Care - Commercial
United Health Care - Empire Plan
United Health Care - Oxford Care
United Health Care - Top Tier
VNSNY Choice Medicare
VillageCareMax
WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
The Patient Experience Star Rating reflects our patients’ perception of how well their Mount Sinai provider communicated with them during an office visit. The Star Rating is based on patient responses to three questions on a patient experience survey, a standardized questionnaire sent to verified patients and distributed by a third party vendor, Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Care Provider’s Explanation
4.8 out of 5
Care Provider’s Concern
4.8 out of 5
Likelihood to Recommend Care Provider
4.7 out of 5
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Tassiulas has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Show More
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Tassiulas has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.